Piper Sandler analyst Adam Maeder maintained a Buy rating on Inari Medical (NARI – Research Report) today and set a price target of $85.00. The company’s shares closed yesterday at $62.87.
Maeder covers the Healthcare sector, focusing on stocks such as Inari Medical, Edwards Lifesciences, and Nevro Corp. According to TipRanks, Maeder has an average return of 13.1% and a 50.52% success rate on recommended stocks.
In addition to Piper Sandler, Inari Medical also received a Buy from BTIG’s Marie Thibault in a report issued on January 1. However, on December 22, Truist Financial maintained a Hold rating on Inari Medical (NASDAQ: NARI).
See the top stocks recommended by analysts >>
Based on Inari Medical’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $126.37 million and a net profit of $3.16 million. In comparison, last year the company earned a revenue of $96.2 million and had a GAAP net loss of $10.15 million
Based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is neutral on the stock. Last month, Hoffman William, a Director at NARI bought 103,492.00 shares for a total of $43,466.64.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inari Medical (NARI) Company Description:
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTreiver product is used for the treatment of pulmonary embolism. Geographically, the company has its presence across the United States.
Read More on NARI:
- Inari Medical price target raised to $70 from $65 at Truist
- Inari Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Inari Medical management to meet virtually with BTIG
- Inari Medical Announces First Patient Enrollment in PEERLESS II Randomized Controlled Trial (RCT)
- Inari Medical announces first patient enrolled in PEERLESS II study
